NewBridge Pharmaceuticals Limited is a British Virgin Island domiciled company with its operating affiliate NewBridge Pharmaceuticals FZ LLC (“NewBridge”) headquartered in Dubai – U.A.E. nbpharma.com
NewBridge is a regional specialty company established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize FDA or EMA approved innovative pharmaceutics, biologics, and other healthcare solutions into the Middle East and Africa regions (MEA). As such, NewBridge serves as a one-stop-solution for our partners providing multi-country access across a wide region with growing economies but complex regulations and access hurdles.
The areas of oncology, immunology, neuroscience, metabolic and rare diseases are NewBridge’s current strategic focus. The existing product portfolio was built to address unmet medical needs in the region and enabled the company not only to gain a sound market share but also to help patients gain access to these much-needed medications. Future expansion includes providing our own branded products through the establishment of manufacturing and development capabilities.
NewBridge’s innovative business model and efficient commercialization reach is built by successful and respected industry leaders with strong local and international track records. In addition, the NewBridge team has competencies in areas of regulatory, medical, pharmacovigilance and commercial capabilities acquired through years of experience in multinational pharma. The team is also well-connected to a wide range of partners and key stakeholders in and out of the region, and offers a flexible approach to joint-ventures and partnerships.
Strong Financial back-up by institutional investors, who provide us with the extensive life science network and diverse investment expertise, support our shared vision of creating a platform of successful alliances in the region.
This integrated and unique strategy of regional expertise coupled with strong international network, position NewBridge as the regional partner-of-choice for pharmaceutical, biotechnology and other healthcare companies seeking access to the rapidly expanding markets of Middle East & Africa.